How is MSI in tumor imaging different from ordinary imaging (CT/MRI)?

CT/MRI see anatomy and morphology, while MSI sees molecular spatial distribution; the two are complementary, with MSI providing the molecular-level tumor-region profile.

What does the melanocytic nevus case illustrate?

The nevus region and normal tissue showed systematic differences in lipid spectral patterns, and the characteristic molecule distribution highly matched the H&E nevus region, suggesting lipids participate in nevus formation and validating the 'imaging + pathology' paradigm.

What is the use of LDPI at 2–3 μm for tumor imaging?

Higher resolution can judge whether molecules localize to fine structures such as a specific cell band or gland, entering single-cell/subcellular scale.

Can tumor MSI results be used directly for clinical diagnosis?

Currently mostly at the research and translation stage; entering clinical use still requires standardization, cohort validation and regulatory procedures.

Application · Mass Spectrometry Imaging

Tumor Imaging: Reading the Molecular Profile Between Tumor Region and Paratumor

The essence of a tumor is not only cell proliferation but also spatial imbalance at the molecular level. Tumor imaging uses mass spectrometry imaging (MSI) to acquire point by point on tumor and adjacent normal tissue, reconstructing this imbalance into a molecular spatial map, helping researchers discover molecules enriched or absent in the tumor region, thereby screening biomarkers and explaining mechanisms.

Table of Contents
1. The Role of MSI in Tumor Imaging 2. Melanocytic Nevus/Cell Tumor Research Case 3. Distinguishing Tumor from Paratumor Tissue 4. Boundary from Research to Clinical Assistance

Tumor Imaging: Reading the Molecular Profile Between Tumor Region and Paratumor — schematic diagram

1. The Role of MSI in Tumor Imaging

The application notes of the Neo-Source MSI DPI list pathology diagnosis as a key area, covering disease biomarker discovery, early diagnosis, clinical pathology research, determining tumor grade and hormone-receptor status. MSI provides in-situ information of 'molecular species + coordinates' that can be registered with H&E and IHC.

Its engineering advantages fit the tumor scenario: matrix-free, low ion suppression, tissue analyzed directly; 20–200 μm adjustable resolution; the section remains intact after imaging for continued H&E or IHC validation.

2. Melanocytic Nevus/Cell Tumor Research Case

In a published DPI case, positive ion mode showed the nevus region mainly presented choline, phosphocholine, S1P, cholesterol, PC and SM, while normal tissue was mostly non-polar lipids such as MAG, DAG and TG; the specific distributions of S1P, cholesterol, PC34:1 and PC38:4 highly matched the H&E nevus region. Negative ion mode presented different PE, PA and PI spectral features, and IHC verified cholesterol aggregation in the nevus region (Talanta, 2021).

This case shows that lipids play an important role in melanocytic nevus formation, and also demonstrates the research paradigm of 'imaging + pathology' combined biomarkers, directly transferable to broader tumor imaging.

3. Distinguishing Tumor from Paratumor Tissue

Distinguishing 'tumor tissue from paratumor tissue' is a strength of MSI. Comparing the molecular spectral differences between the tumor region and adjacent normal tissue can lock molecules specifically enriched or absent as potential diagnostic biomarkers. Multiple sample images in the DPI case showed common distribution patterns, suggesting a basis for establishing discrimination and diagnosis.

For scenarios requiring higher spatial resolution, the Neo-Source MSI LDPI provides 2–3 μm matrix-free ambient imaging, entering the single-cell and even subcellular scale, thereby meeting the higher-resolution need that lies beyond DPI's 20–200 μm range.

4. Boundary from Research to Clinical Assistance

MSI-discovered biomarkers are currently mostly at the research and translation stage; entering clinical diagnosis still requires standardization, cohort validation and regulatory procedures. It has clear value in 'assisting biomarker discovery', 'explaining mechanisms' and 'complementing existing diagnosis'.

Engineered to be compatible with mainstream mass spectrometers from Agilent, AB SCIEX and Thermo, DPI provides a proprietary titanium-alloy ion-transfer tube that does not damage the sample at the front end and is detachable for cleaning, enabling stable and reproducible tumor imaging.

Frequently Asked Questions (FAQ)

How is MSI in tumor imaging different from ordinary imaging (CT/MRI)?: CT/MRI see anatomy and morphology, while MSI sees molecular spatial distribution; the two are complementary, with MSI providing the molecular-level tumor-region profile.
What does the melanocytic nevus case illustrate?: The nevus region and normal tissue showed systematic differences in lipid spectral patterns, and the characteristic molecule distribution highly matched the H&E nevus region, suggesting lipids participate in nevus formation and validating the 'imaging + pathology' paradigm.
What is the use of LDPI at 2–3 μm for tumor imaging?: Higher resolution can judge whether molecules localize to fine structures such as a specific cell band or gland, entering single-cell/subcellular scale.
Can tumor MSI results be used directly for clinical diagnosis?: Currently mostly at the research and translation stage; entering clinical use still requires standardization, cohort validation and regulatory procedures.

Get Specifications & Quotation

To obtain detailed specifications, compatible models, or a quotation for the MSI LDPI / DPI full series imaging ion sources, visit the Neo-Source official website, or contact the official team for compatibility advice tailored to your mass spectrometer (Agilent / SCIEX / Thermo and other mainstream MS).

DPI Dual-Photoionization Imaging Source Neo-Source MSI LDPI Laser Desorption Photoionization imaging ion source Tumor Tissue MSI: 'Reading' Between Tumor Region and Paratumor Distinguishing Tumor from Paratumor Tissue: Drawing the 'Tumor' and 'Non-Tumor' with a Molecular Boundary Tumor Biomarker Localization: Placing 'Biomarkers' into the Real Space of Tumors

← Back to MSI Ion Source Knowledge Hub